Acute respiratory distress syndrome and COVID-19 in a child with systemic lupus erythematosus.
Identifieur interne : 000429 ( Main/Corpus ); précédent : 000428; suivant : 000430Acute respiratory distress syndrome and COVID-19 in a child with systemic lupus erythematosus.
Auteurs : Simone Sukhdeo ; Emily Negroponte ; Hariprem Rajasekhar ; Sunanda Gaur ; Daniel B. Horton ; Amisha Malhotra ; L Nandini MoorthySource :
- Lupus [ 1477-0962 ] ; 2021.
English descriptors
- KwdEn :
- Antiviral Agents (therapeutic use), COVID-19 (complications), COVID-19 (drug therapy), COVID-19 (immunology), Child, Preschool (MeSH), Cytokine Release Syndrome (drug therapy), Cytokine Release Syndrome (etiology), Cytokine Release Syndrome (immunology), Cytokines (antagonists & inhibitors), Disease Progression (MeSH), Enoxaparin (therapeutic use), Glucocorticoids (therapeutic use), Humans (MeSH), Immunosuppressive Agents (therapeutic use), Lupus Erythematosus, Systemic (complications), Lupus Erythematosus, Systemic (drug therapy), Lupus Erythematosus, Systemic (immunology), Male (MeSH), Respiratory Distress Syndrome (drug therapy), Respiratory Distress Syndrome (etiology), Respiratory Distress Syndrome (immunology), SARS-CoV-2 (MeSH).
- MESH :
- chemical , antagonists & inhibitors : Cytokines.
- chemical , therapeutic use : Antiviral Agents, Enoxaparin, Glucocorticoids, Immunosuppressive Agents.
- complications : COVID-19, Lupus Erythematosus, Systemic.
- drug therapy : COVID-19, Cytokine Release Syndrome, Lupus Erythematosus, Systemic, Respiratory Distress Syndrome.
- etiology : Cytokine Release Syndrome, Respiratory Distress Syndrome.
- immunology : COVID-19, Cytokine Release Syndrome, Lupus Erythematosus, Systemic, Respiratory Distress Syndrome.
- Child, Preschool, Disease Progression, Humans, Male, SARS-CoV-2.
Abstract
We report a case of COVID-19 in a pediatric patient with systemic lupus erythematosus (SLE), who presented with respiratory distress marked by increased work of breathing and low oxygen saturation. Lab tests confirmed COVID-19, and showed lymphocytopenia and elevated markers of inflammation and coagulopathy. Chest X-ray showed bilateral mid-lung opacities, and the patient required intubation early in his disease course. Imaging and clinical findings were consistent with acute respiratory distress syndrome (ARDS) with inflammation. The patient was treated with different combinations of antivirals (hydroxychloroquine and remdesivir), cytokine inhibitors (anakinra and tocilizumab), glucocorticoids (hydrocortisone and methylprednisolone), and an anticoagulant (enoxaparin). Inflammatory markers decreased before clinical improvement in lung aeration. This case highlights the potential for pediatric patients with SLE to present with COVID-19 similar to the clinical presentation described in adults.
DOI: 10.1177/0961203321989791
PubMed: 33509065
Links to Exploration step
pubmed:33509065Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Acute respiratory distress syndrome and COVID-19 in a child with systemic lupus erythematosus.</title><author><name sortKey="Sukhdeo, Simone" sort="Sukhdeo, Simone" uniqKey="Sukhdeo S" first="Simone" last="Sukhdeo">Simone Sukhdeo</name><affiliation><nlm:affiliation>Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Negroponte, Emily" sort="Negroponte, Emily" uniqKey="Negroponte E" first="Emily" last="Negroponte">Emily Negroponte</name><affiliation><nlm:affiliation>Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Rajasekhar, Hariprem" sort="Rajasekhar, Hariprem" uniqKey="Rajasekhar H" first="Hariprem" last="Rajasekhar">Hariprem Rajasekhar</name><affiliation><nlm:affiliation>Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Gaur, Sunanda" sort="Gaur, Sunanda" uniqKey="Gaur S" first="Sunanda" last="Gaur">Sunanda Gaur</name><affiliation><nlm:affiliation>Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Horton, Daniel B" sort="Horton, Daniel B" uniqKey="Horton D" first="Daniel B" last="Horton">Daniel B. Horton</name><affiliation><nlm:affiliation>Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Malhotra, Amisha" sort="Malhotra, Amisha" uniqKey="Malhotra A" first="Amisha" last="Malhotra">Amisha Malhotra</name><affiliation><nlm:affiliation>Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Moorthy, L Nandini" sort="Moorthy, L Nandini" uniqKey="Moorthy L" first="L Nandini" last="Moorthy">L Nandini Moorthy</name><affiliation><nlm:affiliation>Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33509065</idno><idno type="pmid">33509065</idno><idno type="doi">10.1177/0961203321989791</idno><idno type="wicri:Area/Main/Corpus">000429</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000429</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Acute respiratory distress syndrome and COVID-19 in a child with systemic lupus erythematosus.</title><author><name sortKey="Sukhdeo, Simone" sort="Sukhdeo, Simone" uniqKey="Sukhdeo S" first="Simone" last="Sukhdeo">Simone Sukhdeo</name><affiliation><nlm:affiliation>Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Negroponte, Emily" sort="Negroponte, Emily" uniqKey="Negroponte E" first="Emily" last="Negroponte">Emily Negroponte</name><affiliation><nlm:affiliation>Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Rajasekhar, Hariprem" sort="Rajasekhar, Hariprem" uniqKey="Rajasekhar H" first="Hariprem" last="Rajasekhar">Hariprem Rajasekhar</name><affiliation><nlm:affiliation>Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Gaur, Sunanda" sort="Gaur, Sunanda" uniqKey="Gaur S" first="Sunanda" last="Gaur">Sunanda Gaur</name><affiliation><nlm:affiliation>Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Horton, Daniel B" sort="Horton, Daniel B" uniqKey="Horton D" first="Daniel B" last="Horton">Daniel B. Horton</name><affiliation><nlm:affiliation>Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Malhotra, Amisha" sort="Malhotra, Amisha" uniqKey="Malhotra A" first="Amisha" last="Malhotra">Amisha Malhotra</name><affiliation><nlm:affiliation>Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Moorthy, L Nandini" sort="Moorthy, L Nandini" uniqKey="Moorthy L" first="L Nandini" last="Moorthy">L Nandini Moorthy</name><affiliation><nlm:affiliation>Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Lupus</title><idno type="eISSN">1477-0962</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>COVID-19 (complications)</term><term>COVID-19 (drug therapy)</term><term>COVID-19 (immunology)</term><term>Child, Preschool (MeSH)</term><term>Cytokine Release Syndrome (drug therapy)</term><term>Cytokine Release Syndrome (etiology)</term><term>Cytokine Release Syndrome (immunology)</term><term>Cytokines (antagonists & inhibitors)</term><term>Disease Progression (MeSH)</term><term>Enoxaparin (therapeutic use)</term><term>Glucocorticoids (therapeutic use)</term><term>Humans (MeSH)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Lupus Erythematosus, Systemic (complications)</term><term>Lupus Erythematosus, Systemic (drug therapy)</term><term>Lupus Erythematosus, Systemic (immunology)</term><term>Male (MeSH)</term><term>Respiratory Distress Syndrome (drug therapy)</term><term>Respiratory Distress Syndrome (etiology)</term><term>Respiratory Distress Syndrome (immunology)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Cytokines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Enoxaparin</term><term>Glucocorticoids</term><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>COVID-19</term><term>Lupus Erythematosus, Systemic</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term><term>Cytokine Release Syndrome</term><term>Lupus Erythematosus, Systemic</term><term>Respiratory Distress Syndrome</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cytokine Release Syndrome</term><term>Respiratory Distress Syndrome</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>COVID-19</term><term>Cytokine Release Syndrome</term><term>Lupus Erythematosus, Systemic</term><term>Respiratory Distress Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Child, Preschool</term><term>Disease Progression</term><term>Humans</term><term>Male</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We report a case of COVID-19 in a pediatric patient with systemic lupus erythematosus (SLE), who presented with respiratory distress marked by increased work of breathing and low oxygen saturation. Lab tests confirmed COVID-19, and showed lymphocytopenia and elevated markers of inflammation and coagulopathy. Chest X-ray showed bilateral mid-lung opacities, and the patient required intubation early in his disease course. Imaging and clinical findings were consistent with acute respiratory distress syndrome (ARDS) with inflammation. The patient was treated with different combinations of antivirals (hydroxychloroquine and remdesivir), cytokine inhibitors (anakinra and tocilizumab), glucocorticoids (hydrocortisone and methylprednisolone), and an anticoagulant (enoxaparin). Inflammatory markers decreased before clinical improvement in lung aeration. This case highlights the potential for pediatric patients with SLE to present with COVID-19 similar to the clinical presentation described in adults.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33509065</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Acute respiratory distress syndrome and COVID-19 in a child with systemic lupus erythematosus.</ArticleTitle><Pagination><MedlinePgn>836-839</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0961203321989791</ELocationID><Abstract><AbstractText>We report a case of COVID-19 in a pediatric patient with systemic lupus erythematosus (SLE), who presented with respiratory distress marked by increased work of breathing and low oxygen saturation. Lab tests confirmed COVID-19, and showed lymphocytopenia and elevated markers of inflammation and coagulopathy. Chest X-ray showed bilateral mid-lung opacities, and the patient required intubation early in his disease course. Imaging and clinical findings were consistent with acute respiratory distress syndrome (ARDS) with inflammation. The patient was treated with different combinations of antivirals (hydroxychloroquine and remdesivir), cytokine inhibitors (anakinra and tocilizumab), glucocorticoids (hydrocortisone and methylprednisolone), and an anticoagulant (enoxaparin). Inflammatory markers decreased before clinical improvement in lung aeration. This case highlights the potential for pediatric patients with SLE to present with COVID-19 similar to the clinical presentation described in adults.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sukhdeo</LastName><ForeName>Simone</ForeName><Initials>S</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-9460-5200</Identifier><AffiliationInfo><Affiliation>Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Negroponte</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajasekhar</LastName><ForeName>Hariprem</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaur</LastName><ForeName>Sunanda</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horton</LastName><ForeName>Daniel B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malhotra</LastName><ForeName>Amisha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moorthy</LastName><ForeName>L Nandini</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017984">Enoxaparin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017984" MajorTopicYN="N">Enoxaparin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ARDS</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">pediatric</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>29</Day><Hour>5</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33509065</ArticleId><ArticleId IdType="doi">10.1177/0961203321989791</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000429 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000429 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:33509065
|texte= Acute respiratory distress syndrome and COVID-19 in a child with systemic lupus erythematosus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33509065" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |